Key facts
- A poll found strong bipartisan support among battleground voters for codifying President Trump's "most favored nation" drug pricing policy.
- The policy would require pharmaceutical companies to match U.S. prices to those charged in other countries.
- 91% of battleground voters support the "most favored nation" idea.
- 65% of voters specifically support Congress passing legislation to codify the policy into law.
- President Trump has called on Congress to enact the policy, but GOP lawmakers have been muted.
Voters in battleground states show strong bipartisan support for codifying President Trump's "most favored nation" drug pricing policy, according to a new poll. The policy aims to lower prescription drug costs for Americans by requiring pharmaceutical companies to match prices charged in other countries.
The poll, conducted by Democratic firm Lake Research Partners, found that drug pricing is a high-priority issue for voters ahead of the midterm elections. Nearly 60 percent of voters believe current prescription drug prices are still too high and that the federal government needs to do more to reduce them, with 90 percent deeming congressional action important.
Specifically, 91 percent of battleground voters support the "most favored nation" concept, and 85 percent indicated they would be more likely to vote for a candidate who backs it. The survey of 1,200 registered voters across five states and 33 competitive House districts revealed that 65 percent specifically support Congress passing legislation to enact this policy into law.
President Trump and his administration have urged Congress to legislate the "most favored nation" policy, which currently exists as voluntary agreements with 17 drug companies that lack enforcement mechanisms without congressional action. However, Republican lawmakers have largely remained quiet on the prospect of codifying the policy.